Dual-targeting of EGFR and Neuropilin-1 attenuates resistance to EGFR-targeted antibody therapy in KRAS-mutant non-small cell lung cancer-Reference-Cited by-同舟云学术

Dual-targeting of EGFR and Neuropilin-1 attenuates resistance to EGFR-targeted antibody therapy in KRAS-mutant non-small cell lung cancer

Published:2019-12 Issue: Volume:466 Page:23-34
ISSN:0304-3835
Container-title:Cancer Letters
language:en
Short-container-title:Cancer Letters

Author:

Kim Ye-Jin,Baek Du-San,Lee Seyoung,Park Daechan,Kang Han Na,Cho Byoung Chul^ORCID,Kim Yong-Sung^ORCID

Funder

National Research Foundation

Ministry of Science, ICT & Future Planning, Republic of Korea

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference39 articles.

1. Early stage and locally advanced (non-metastatic) non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up;Crino;Ann. Oncol.,2010

2. Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer Is correlated with survival;Brabender;Clin. Cancer Res.,2001

3. Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial;Thatcher;Lancet Oncol.,2015

4. Understanding and targeting resistance mechanisms in NSCLC;Rotow;Nat. Rev. Cancer,2017

5. A comprehensive survey of Ras mutations in cancer;Prior;Cancer Res.,2012

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unlocking the potential of bispecific ADCs for targeted cancer therapy;Frontiers of Medicine;2024-07-23

2. VEGFA/NRP-1/GAPVD1 axis promotes progression and cancer stemness of triple-negative breast cancer by enhancing tumor cell-macrophage crosstalk;International Journal of Biological Sciences;2024

3. Chimeric antigen receptor-T cells are effective against CEACAM5 expressing non-small cell lung cancer cells resistant to antibody-drug conjugates;Frontiers in Oncology;2023-02-27

4. Expanding the Therapeutic Window of EGFR-Targeted PE24 Immunotoxin for EGFR-Overexpressing Cancers by Tailoring the EGFR Binding Affinity;International Journal of Molecular Sciences;2022-12-13

5. Neuropilin (NRPs) Related Pathological Conditions and Their Modulators;International Journal of Molecular Sciences;2022-07-29